Table 3.
Baseline viral co-infections of study participants.
| Overall | Discovery cohort | Validation cohort | |
|---|---|---|---|
| Positive HAV serology, N (%) | 1108 (58.5%) | 1096 (70.3%) | 48 (14.2%) |
| Previous infection, N (%) | 221 (11.7%) | 204 (13.1%) | 17 (5.1%) |
| Previous vaccination, N (%) | 347 (18.3%) | 317 (20.3%) | 30 (8.9%) |
| HAV antibodies present, unknown if acquired through vaccination or infection, N (%) | 540 (28.5%) | 539 34.6%) | 1 (0.3%) |
| Negative HAV serology, N (%) | 318 (16.8%) | 309 (19.8%) | 9 (2.7%) |
| Unknown HAV serology, N (%) | 469 (24.7%) | 190 (12.2%) | 279 (83.0%) |
| Positive HBV serology, N (%) | 1518 (80.1%) | 1296 (83.1%) | 222 (66.1%) |
| Previous infection, N (%) | 634 (33.5%) | 537 (34.4%) | 97 (28.9%) |
| Previous vaccination, N (%) | 831 (43.9%) | 715 (45.9%) | 116 (34.5%) |
| Chronic ART-suppressed infection, N (%) | 53 (2.8%) | 44 (2.8%) | 9 (2.7%) |
| Negative HBV serology, N (%) | 260 (13.7%) | 224 (14.4%) | 36 (10.7%) |
| Unknown HBV serology, N (%) | 117 (6.2%) | 39 (2.5%) | 78 (23.1%) |
| Known previous HCV infection, N (%) | 172 (9.1%) | 147 (9.4%) | 25 (7.4%) |
| Serum available for CMV serology, N (%) | 1887 (99.6%) | 1553 (99.6%) | 334 (99.4%) |
| Positive CMV IgG serology, N (%) | 1770 (93.8%) | 89 (5.7%) | 28 (8.3%) |
| CMV IgG titer in IU/mL, median (IQR) | 690 (400-904) | 682 (391-900) | 703 (439-941) |
HAV, Hepatitis A Virus; HBV, Hepatitis B infection; HCV, Hepatitis C Virus; CMV, Cytomegalovirus; IgG, Immunoglobulin G; IU, International Units; mL, Milliliter; N, Number of Participants; IQR, Inter Quartile Range.